On 26 November 2024, The Economic Times reported that AstraZeneca has received approval from India’s Central Drugs Standard Control Organisation (CSDCO) to market Lynparza® (olaparib) in India.
The CDSCO granted approval for the use of Lynparza® in combination with durvalumab for the maintenance treatment of advanced or recurrent endometrial cancer in adults whose disease has not progressed on first-line platinum-based chemotherapy. Lynparza® received Indian approval in August 2022 as a monotherapy for adjuvant treatment of patients with high-risk early breast cancer.
This follows European approval of the combination treatment in August 2024. AstraZeneca confirmed in August 2024 that regulatory submissions for Imfinzi® and Lynparza® were (then) under review in Japan and several other countries.